Incyte Corporation maintained revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues $325 million to $360 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.88 USD | -0.30% | +6.32% | -9.41% |
May. 15 | Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.41% | 12.81B | |
-1.23% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B | |
-7.11% | 7.06B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Maintains Revenue Guidance for 2024